Catalyst Pharmaceuticals Incorporated (NASDAQ:CPRX) Just Reported Decreased Shorts

January 14, 2018 - By Adrian Erickson

 Catalyst Pharmaceuticals Incorporated (NASDAQ:CPRX) Just Reported Decreased Shorts

Investors sentiment decreased to 2 in Q3 2017. Its down 0.22, from 2.22 in 2017Q2. It turned negative, as 3 investors sold Catalyst Pharmaceuticals, Inc. shares while 15 reduced holdings. 17 funds opened positions while 19 raised stakes. 34.72 million shares or 4.30% more from 33.29 million shares in 2017Q2 were reported.
446,407 were accumulated by Deutsche Bancshares Ag. Creative Planning owns 10,681 shares for 0% of their portfolio. Broadfin Capital Ltd Llc invested in 6.89 million shares. Tower Cap Llc (Trc) has invested 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Balyasny Asset Mgmt Ltd Limited Liability Company invested in 0% or 14,800 shares. 57,050 are held by Sg Americas Securities Llc. Aqr Capital Mgmt Lc has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Alliancebernstein L P reported 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Hbk Sorce Advisory Ltd Liability Com holds 21,109 shares. Kings Point Capital accumulated 0% or 6,000 shares. Commercial Bank Of America Corp De holds 7,132 shares. California Public Employees Retirement System owns 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 41,332 shares. Knott David M accumulated 365,110 shares or 0.39% of the stock. First Allied Advisory Inc has 0% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 26,000 shares. Berson & Corrado Invest Lc holds 95,100 shares or 0.14% of its portfolio.

The stock of Catalyst Pharmaceuticals Incorporated (NASDAQ:CPRX) registered a decrease of 19.53% in short interest. CPRX’s total short interest was 2.63 million shares in January as published by FINRA. Its down 19.53% from 3.27 million shares, reported previously. With 2.73 million shares average volume, it will take short sellers 1 days to cover their CPRX’s short positions. The short interest to Catalyst Pharmaceuticals Incorporated’s float is 4.63%.

The stock decreased 0.76% or $0.03 during the last trading session, reaching $3.92. About 262,946 shares traded. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 267.48% since January 14, 2017 and is uptrending. It has outperformed by 250.78% the S&P500.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $401.70 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and TouretteÂ’s disorder; and CPP-109 to treat TouretteÂ’s disorder.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ratings Coverage

Among 5 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals had 13 analyst reports since April 26, 2016 according to SRatingsIntel. The stock has “Buy” rating by Piper Jaffray on Monday, August 7. Piper Jaffray downgraded the shares of CPRX in report on Tuesday, April 26 to “Neutral” rating. PiperJaffray upgraded it to “Overweight” rating and $4 target in Wednesday, October 5 report. The stock has “Buy” rating by Roth Capital on Wednesday, August 30. The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has “Overweight” rating given on Wednesday, October 5 by Piper Jaffray. The firm earned “Buy” rating on Tuesday, October 31 by SunTrust. The stock has “Buy” rating by Roth Capital on Thursday, August 10. Roth Capital maintained it with “Buy” rating and $4.75 target in Wednesday, November 1 report. The company was maintained on Monday, November 27 by SunTrust. The rating was maintained by H.C. Wainwright with “Buy” on Friday, August 11.

More news for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) were recently published by: Prnewswire.com, which released: “Generic Drugs Stocks’ Research Reports Released on Catalyst Pharma, Flexion …” on January 09, 2018. Zacks.com‘s article titled: “What Drives Catalyst Pharmaceuticals Above 250% This Year?” and published on December 28, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.